Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval

by Ebenezer Tumban
Published 2021-12-01

A Current Update on Human Papillomavirus-Associated Head and Neck Cancers

by Ebenezer Tumban
Published 2019-10-01

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?

by Rashi Yadav, Lukai Zhai, Ebenezer Tumban
Published 2019-12-01

A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.

by Ebenezer Tumban, Julianne Peabody, David S Peabody, Bryce Chackerian
Published 2011-01-01

Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature

by Julianne Peabody, Pavan Muttil, Bryce Chackerian, Ebenezer Tumban
Published 2017-06-01

VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.

by Ebenezer Tumban, Julianne Peabody, Mitchell Tyler, David S Peabody, Bryce Chackerian
Published 2012-01-01

Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51

by Rashi Yadav, Lukai Zhai, Nitesh K. Kunda, Pavan Muttil, Ebenezer Tumban
Published 2021-06-01